登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TL1A】

TL1A信息

英文名称:Tumor necrosis factor superfamily member 15
中文名称:肿瘤坏死因子超家族成员15
靶点别称:VEGI192A,Vascular Endothelial Cell Growth Inhibitor,TNF Superfamily Ligand TL1A,TNFSF15,Tumor Necrosis Factor (Ligand) Superfamily, Member 15,Vascular Endothelial Growth Inhibitor-192A,VEGI,TL1A,Tumor Necrosis Factor Ligand 1B,TNLG1B,TNF Superfamily Member 15,Tumor Necrosis Factor Superfamily Member 15,TL1,TNF Ligand-Related Molecule 1,Tumor Necrosis Factor Ligand Superfamily Member 15,MGC129934,MGC129935
上市药物数量:0
临床药物数量:4
最高研发阶段:临床三期

抗体项目交易平台

项目名称 项目阶段 分子类型 分子来源 疾病领域 适应症

Licensing 项目合作

项目名称 药物类型 治疗领域 适应症 阶段 权益地区

TL1A分子别名

TL1A, VEGI, TNFSF15

TL1A分子背景

TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

TL1A临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Tulisokibart PRA-023; MK-7240; PRA023 临床三期 Prometheus Biosciences Inc, Merck Sharp & Dohme LLC 炎症性肠疾病, 间质性肺疾病, 溃疡性结肠炎, 弥漫性硬皮病, 克罗恩病 详情
RVT-3101 PF-06480605; PF 6480605; RVT-3101 临床二期 辉瑞 炎症性肠疾病, 溃疡性结肠炎, 克罗恩病 详情
TEV-48574 TEV-48574 临床二期 以色列梯瓦制药工业有限公司 溃疡性结肠炎, 哮喘, 克罗恩病 详情
Next-generation anti-TL1A antibody(Telavant) 临床一期 Telavant Inc 纤维化, 炎性疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定